litlas
Log inCreate account

Ruben A. Mesa

Active 1997–2025

Also published as
Ruben A Mesa
218
Papers
36,815
Citations
96
h-index
204
i10-index

Citations

Citations per year for Ruben A. Mesa1997: 1 citations1999: 4 citations2000: 10 citations2001: 20 citations2002: 9 citations2003: 27 citations2004: 39 citations2005: 80 citations2006: 128 citations2007: 181 citations2008: 208 citations2009: 227 citations2010: 213 citations2011: 223 citations2012: 246 citations2013: 318 citations2014: 258 citations2015: 301 citations2016: 270 citations2017: 279 citations2018: 241 citations2019: 786 citations2020: 1,514 citations2021: 1,380 citations2022: 1,114 citations2023: 787 citations2024: 1,262 citations2025: 444 citations2026: 8 citations1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,442 citing papers, 27.4% of this breakdownItaly: 741 citing papers, 8.3% of this breakdownUnited Kingdom: 612 citing papers, 6.9% of this breakdownGermany: 603 citing papers, 6.8% of this breakdownFrance: 503 citing papers, 5.6% of this breakdownChina: 448 citing papers, 5% of this breakdownSpain: 330 citing papers, 3.7% of this breakdownCanada: 283 citing papers, 3.2% of this breakdownAustralia: 223 citing papers, 2.5% of this breakdownSwitzerland: 222 citing papers, 2.5% of this breakdownAustria: 173 citing papers, 1.9% of this breakdownNetherlands: 165 citing papers, 1.9% of this breakdown
0%27.4%Other 24.3%

Institutions

Fields

  • Medicine83.8%
  • Biochemistry, Genetics and Molecular Biology9.3%
  • Immunology and Microbiology3.5%
  • Psychology0.8%
  • Chemistry0.4%
  • Social Sciences0.4%
  • Other1.8%

Topics

  • Myeloproliferative Neoplasms: Diagnosis and Treatment14.7%
  • Acute Myeloid Leukemia Research9.1%
  • Chronic Myeloid Leukemia Treatments5%
  • Kruppel-like factors research4.8%
  • Eosinophilic Disorders and Syndromes4.8%
  • COVID-19 and healthcare impacts3.7%
  • Other57.9%

Coauthors

All papers

Open in search
  1. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Authors: Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson‐Viitanen, Iphigenia L. Koumenis, William Sun, Victor Sandor, Hagop M. Kantarjian - New England Journal of Medicine 2012 cited by 2,050

  2. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

    Authors: Ross L. Levine, Martha Wadleigh, Jan Cools, Benjamin L. Ebert, Gerlinde Wernig, Brian J.P. Huntly, Titus J. Boggon, Iwona Włodarska, Jennifer Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey C. Lee, Stacey Gabriel, Thomas Mercher, Alan D. D’Andrea, Stefan Fröhling, Konstanze Döhner, Peter Marynen, Peter Vandenberghe, Ruben A. Mesa, Ayalew Tefferi, James D. Griffin, Michael J. Eck, William R. Sellers, Matthew Meyerson, Todd R. Golub, Stephanie J. Lee, D. Gary Gilliland - Cancer Cell 2005 cited by 2,991

  3. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    Authors: Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu, Miklós Egyed, María Laura Fox, Donal P. McLornan, Andrew C. Perkins, Sung‐Soo Yoon, Vikas Gupta, Jean‐Jacques Kiladjian, Nikki Granacher, Sung‐Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire Harrison, Barbara Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben A. Mesa, Adi Shacham Abulafia, Haifa Kathrin Al‐Ali, Björn Andréasson, Anna Angona, Rosa Ayala, Soo‐Mee Bang, Bruce Bank, Fiorenza Barraco, Eloise Beggiato, Fleur Samantha Benghiat, Massimiliano Bonifacio, Claire Bories, Gabriela Borsaru, Mette Brabrand, Andrei Braester, Andes Broliden, Veronika Buxhofer‐Ausch, Nathalie Cambier, Marianna Caramella, Benjamin Carpentier, Nicola Cascavilla, Maria Giraldo Castellano, Hung Chang, Chih‐Cheng Chen, June‐Won Cheong, Yunsuk Choi, Philip Choi, Maria Teresa Corsetti, Isabel Montero Cuadrado, Julia Cunningham, Gandhi Damaj, Valerio De Stefano, Robert Delage, Regina Garcĺa Delgado, José Miguel Torregrosa Diaz, Péter Dombi, Viviane Dubruille, Miklós Egyed, Daniel El Fassi, Anna Elinder-Camburn, Elena Maria Elli, Martin Ellis, Carmen Fava, Salman Fazal, Angela Fleischman, Lynda Foltz, María Laura Fox, Nashat Gabrail, Jose Valentĺn Garcĺa-Gutiérrez, Aaron T. Gerds, Stéphane Girault, Heinz Gisslinger, Alexandru Gluvacov, Yeow Tee Goh, Joachim R. Göthert, Nikki Granacher, Sebastian Grosicki, Vikas Gupta, Evgeni Hadjiev, Kaoutar Hafraoui, Aryan Hamed, Claire Harrison, Hans Carl Hasselbalch, Hanns Hauser, Mark Heaney, Holger Hebart, Jesús María Hernández‐Rivas, Victor Higuero Saavedra, Christopher Hillis, Hsin‐An Hou, Jonathan P. How, Daniel Huang, Marek Hus and 95 more - The Lancet 2023 cited by 185

  4. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

    Authors: Animesh Pardanani, Claire Harrison, Jörge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Éric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Abhay Patki, Guozhi Gao, Ayalew Tefferi - JAMA Oncology 2015 cited by 472

  5. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

    Authors: Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib - Journal of Clinical Oncology 2017 cited by 367

  6. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

    Authors: John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady L. Stein, Vikas Gupta, Anita Szőke, Mark W. Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, Suliman Al‐Fayoumi, Jennifer Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben A. Mesa, Srđan Verstovšek - JAMA Oncology 2018 cited by 380

  7. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

    Authors: Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher, Aimee Jackson, Christina Yap, Jennifer O’Sullivan, Sonia Fox, Isaak Ailts, Amylou C. Dueck, Holly L. Geyer, Ruben A. Mesa, William G. Dunn, Eugene Nadezhdin, Natalia Curto‐García, Anna Green, Bridget S. Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Frederick Chen, Ioannis Koutsavlis, Anna L. Godfrey, Siamak Arami, Mark W. Drummond, Jenny Byrne, Fiona Clark, Carolyn Mead‐Harvey, E. Joanna Baxter, Mary Frances McMullin, Adam J. Mead - Journal of Clinical Oncology 2023 cited by 142

  8. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    Authors: Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Ruben A. Mesa, Shui He, Mark M. Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srđan Verstovšek - New England Journal of Medicine 2015 cited by 872

  9. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

    Authors: Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, Francesco Passamonti, Richard T. Silver, Ronald Hoffman, Srđan Verstovšek, Ruben A. Mesa, Jean‐Jacques Kiladjian, Rȕdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary Frances Mc Mullin, Hans Carl Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kröger, Martin Grießhammer, Gunnar Birgegård, Giovanni Barosi - Leukemia 2018 cited by 552

  10. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

    Authors: Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T. Reilly, Enrica Morra, Alessandro M. Vannucchi, Ruben A. Mesa, Jean‐Loup Demory, Giovanni Barosi, Elisa Rumi, Ayalew Tefferi - Blood 2008 cited by 1,237

  11. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Authors: Ayalew Tefferi, Francisco Cervantes, Ruben A. Mesa, Francesco Passamonti, Srđan Verstovšek, Alessandro M. Vannucchi, Jason Gotlib, Brigitte Dupriez, Animesh Pardanani, Claire Harrison, Ronald Hoffman, Heinz Gisslinger, Nicolaus Kröger, Jüergen Thiele, Tiziano Barbui, Giovanni Barosi - Blood 2013 cited by 379

  12. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

    Authors: for the COMFORT-I investigators, Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark M. Jones, Deanna Kornacki, Kang Sun, Hagop M. Kantarjian - Journal of Hematology & Oncology 2017 cited by 427

  13. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

    Authors: John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O'Connell, Jean-Jacques Kiladjian, Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max F. Levine, Juan E. Arango Ossa, Erin McGovern, Lonette Sandy, Mohamad E. Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V. Penson, Rona Singer Weinberg, Leah Price, Judith D. Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman - Blood 2022 cited by 129

  14. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

    Authors: Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Ramón V. Tiu, Pierre Zachée, Éric Jourdan, Elliott F. Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa - The Lancet Haematology 2017 cited by 330

  15. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

    Authors: Nicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, Markus Ditschkowski, Nico Gagelmann, Martin Grießhammer, Vikas Gupta, Nada Hamad, Claire Harrison, Juan Carlos Hernández‐Boluda, Steffen Koschmieder, Tania Jain, John Mascarenhas, Ruben A. Mesa, Uday Popat, Francesco Passamonti, Nicola Polverelli, Alessandro Rambaldi, Marie Robin, Rachel B. Salit, Thomas Schroeder, Bart L. Scott, Roni Tamari, Ayalew Tefferi, Alessandro M. Vannucchi, Donal P. McLornan, Giovanni Barosi - The Lancet Haematology 2023 cited by 96

  16. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Authors: Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Jean‐Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter A.W. te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández‐Maraver, Heike L. Pahl, Martin Grießhammer, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Françoise Boyer, Gabriel Étienne, Jean‐Christophe Ianotto, Dana Ranta, Lydia Roy, Jean‐Yves Cahn, Claire Harrison, Deepti Radia, Pablo Muxí, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Björn Andréasson, Maria L Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegård, Ayalew Tefferi, Ruben A. Mesa - Journal of Clinical Oncology 2012 cited by 458

  17. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Authors: Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa, Animesh Pardanani, Jörge E. Cortes, Deborah A. Thomas, Zeev Estrov, Jordan S. Fridman, Edward C. Bradley, Susan Erickson‐Viitanen, Kris Vaddi, Richard Levy, Ayalew Tefferi - New England Journal of Medicine 2010 cited by 1,165

  18. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    Authors: Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih–Yuan Hsu, Aakash Desai, Gilberto Lopes, Petros Grivas, Corrie Painter, Solange Peters, Michael A Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii‐Saab, Mehmet Asım Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo and 136 more - The Lancet 2020 cited by 1,802

  19. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

    Authors: Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead, Miklós Egyed, Anita Szőke, Aleksandr Suvorov, János Jakucs, Andrew C. Perkins, Ritam Prasad, Jiřı́ Mayer, Judit Demeter, Peter Ganly, Jack W. Singer, Huafeng Zhou, James P. Dean, Peter A. te Boekhorst, Jyoti Nangalia, Jean‐Jacques Kiladjian, Claire Harrison - The Lancet Haematology 2017 cited by 314

  20. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

    Authors: Srđan Verstovšek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Francisco Cervantes, Claire Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta - Journal of Hematology & Oncology 2017 cited by 298

  21. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

    Authors: Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Ruben A. Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark Heaney, Casey L. O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann - Blood Advances 2020 cited by 123

  22. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

    Authors: Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian, Jason Gotlib, F. Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, V. Sandor, P. Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srđan Verstovšek, on behalf of the COMFORT Investigators - Haematologica 2015 cited by 253

  23. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

    Authors: Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean‐Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah Buckley, Shanthakumar Tyavanagimatt, Bryan Harder, Karisse Roman‐Torres, Jennifer A. Smith, Adam R. Craig, John Mascarenhas, Srđan Verstovšek - Blood Advances 2023 cited by 73

  24. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

    Authors: Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T. Oh, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Miklós Egyed, Jiřı́ Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire Harrison - Blood Advances 2023 cited by 48